Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism - Wikidata - awgldk - TriplyDB

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

http://www.wikidata.org/entity/Q34213621

about

Sex Differences in the Blood Concentration of Tacrolimus in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients with CYP3A5*3/*3 CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.In vitro study of the variable effects of proton pump inhibitors on voriconazole Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.A retrospective analysis of patient-specific factors on voriconazole clearance.Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Pharmacogenomics of the triazole antifungal agent voriconazole.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.PharmGKB summary: voriconazole pathway, pharmacokinetics.In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults.CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.Association of rs2254638 Polymorphism With Clopidogrel Response in Chinese Patients With Coronary Artery Disease

P2860

Q33710324-BDB1959A-009B-469E-85F0-0C2D9241613F Q33849298-182582CB-10D5-4E2A-ABB1-AC9A15E466B0 Q35169112-A0D7BA44-0780-477D-BD19-A9892EB0AF14 Q35617669-9381411C-DFB6-4EF2-8D52-1E7B089E35A1 Q35960842-17F86094-B87F-4E4A-BA99-2A8074036B2A Q36365500-BAB32A9D-334E-43AA-B224-246CB1FF7DC6 Q36608562-34202B53-90AD-42A5-8080-4B6B38B26D73 Q36810454-E1C4FAFE-9C13-4A20-9812-8EBC5614A7AD Q37207816-EE430C77-7747-45DD-A859-D108024BB2FA Q37892536-456F2FDA-3F0A-43E7-9C95-6933F22E6317 Q38526795-387352C3-CBB4-473A-AE9B-A8EFE2D03814 Q38775809-17C5404D-C368-4D26-8C79-29594C58DBA9 Q38889189-31D39052-EAA6-4DB8-AB16-C7F238256B0B Q38918175-3332FE36-B451-48A6-9BD0-6A3E34801350 Q41986948-1666E244-8BB3-4271-9052-B23F4D2AD478 Q44197195-182B66FF-DF8D-4232-AE62-CA3FCAB501C6 Q44401287-BB3A4160-A965-4274-9096-92A35F4BF05E Q47664190-2593C564-F53E-4ED4-B33D-FA0A54223959 Q48010621-1CDFDDE3-6289-4B5D-B273-B384CCDB06F4 Q50112710-1B6BCFC8-7B94-4471-9BA1-86813BC8DB77 Q51631938-4E8287BB-09C6-4486-B87A-B73B59EA0E27 Q57072916-5B63A208-4A89-4641-97E8-2A3C4DF9F96A

P2860

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

http://www.wikidata.org/entity/Q34213621

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@ast

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@en

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@nl

type

label

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@ast

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@en

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@nl

prefLabel

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@ast

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@en

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@nl

P1433

Q34213621-5ECC3E7C-DC8B-49BF-AEDD-F66CE2C28AEF

P1476

Q34213621-A2318751-B07A-4876-85EB-BAA6145075DE

P2093

Q34213621-080A8423-ABF9-43C8-8B8A-329FAE37818D

Q34213621-2B5056D6-881A-4C05-A9EA-D9A9B8032E16

Q34213621-3BF70D36-A39A-47DD-9451-7A621BE96C0F

Q34213621-5D076D59-BAFF-487A-9CCC-16C40E57437D

Q34213621-7B36341B-2DC1-4E01-925B-42E361151FB3

Q34213621-7DC6EE5F-3235-410D-BE20-D7B8CFFA7C61

Q34213621-AD390F0A-2282-4361-86B4-C3B1488347CB

Q34213621-BB998169-B36D-41E6-912F-7A09C6CBBDCE

Q34213621-E9F61618-D7C2-49CE-A8CA-619DECC9A4DF

P2860

Q34213621-0B742F64-AAAE-413C-9B0B-D76F2EE59AF7

Q34213621-14A062D7-F9D3-4349-8E4A-9160F89D5780

Q34213621-15E9CDEF-CC15-4EE6-8BA6-10EEA0A2EE42

Q34213621-1D44994C-76CF-4521-B002-5C0520ADDCDD

Q34213621-20402009-3A76-4E1F-A6B5-80F94B5B7D38

Q34213621-2376E844-6C99-4134-A028-B7BF931024D5

Q34213621-2442119E-128D-4F99-A01E-28F7593CEC15

Q34213621-29A151F5-C4E9-4FB6-A7E2-29C82CFBD737

Q34213621-2C7382E9-AA4B-4973-AB93-6F9904F0A639

Q34213621-30EA969F-240C-44F2-B877-7A9E56EC64EB

P2888

Q34213621-A9C0504B-F4B3-4930-9F66-B8929F1BC275

P304

Q34213621-F5482D6A-15A7-4E3C-B335-7F485027D65A

P31

Q34213621-9F3A39FA-0DBE-4602-9116-8D7A62EBF2DA

P356

Q34213621-60D7AD5D-8412-4FED-94DE-EB288A41E760

P433

Q34213621-A26F7C90-AFF3-472D-98E7-4748429D9683

P478

Q34213621-6DABDE79-EE65-44EA-BA4B-DF0C288D0E22

P577

Q34213621-218616A4-A3CF-4048-B608-2E22EBB5CF84

P5875

Q34213621-A9CCA8D6-1314-4645-94F2-BB935C91DB05

P6179

Q34213621-1BDF7E03-CF6D-4DF3-83C8-FC38C3E2AF0D

P698

Q34213621-1DDF24F4-DEB4-4349-9FBB-03CB2C2F7D95

P932

Q34213621-65688024-6B4B-4E9F-A3F9-975A4808E3D6

P356

S00228-010-0869-3

P1433

European Journal of Clinical Pharmacology

P1476

Effects of erythromycin on vor ...... tion with CYP2C19 polymorphism

@en

P2093

Dong-Sheng Ouyang

http://www.w3.org/2001/XMLSchema#string

Gan Zhou

http://www.w3.org/2001/XMLSchema#string

Guo-Ping Yang

http://www.w3.org/2001/XMLSchema#string

Hui-Yan Shi

http://www.w3.org/2001/XMLSchema#string

Jin Yan

http://www.w3.org/2001/XMLSchema#string

Wei-Hua Wu

http://www.w3.org/2001/XMLSchema#string

Wen-Hui Zhu

http://www.w3.org/2001/XMLSchema#string

Xiao-Ping Chen

http://www.w3.org/2001/XMLSchema#string

Zhi-Rong Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Current and emerging azole antifungal agents

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans

Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele

CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Review of the safety and efficacy of voriconazole.

Voriconazole -- better chances for patients with invasive mycoses.

Pharmacokinetic drug interactions of macrolides.

P2888

s00228-010-0869-3

P304

1131-1136

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-010-0869-3

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45407363

http://www.w3.org/2001/XMLSchema#string

P6179

1030133142

http://www.w3.org/2001/XMLSchema#string

P698

20669013

http://www.w3.org/2001/XMLSchema#string

P932

2957581

http://www.w3.org/2001/XMLSchema#string